Oncotype DX Assay May Help Guide Node Positive, ER+ Breast Cancer Treatment | GenomeWeb

NEW YORK (GenomeWeb News) â€" In a pair of papers appearing online today in the Lancet and Lancet Oncology, members of the Breast Cancer Intergroup of North America reported that some post-menopausal, estrogen receptor positive breast cancer patients benefit from the addition of chemotherapy to standard tamoxifen treatment.

And, the researchers found, the addition of chemotherapy was most beneficial for individuals scoring high on Genomic Health's Oncotype DX test, suggesting the recurrence assay may be helpful for guiding such treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.